Management of Covert Hepatic Encephalopathy

Clinics in Liver Disease

Volumn 16, Issue 1, 2012, Pages 91-93

  Mullen, Kevin D ^a   Prakash, Ravi K ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Covert hepatic encephalopathy; Hepatic encephalopathy; Minimal hepatic encephalopathy; Psychometric hepatic encephalopathy score

Indexed keywords

LACTULOSE; RIFAXIMIN;

CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; COVERT HEPATIC ENCEPHALOPATHY; DISEASE SEVERITY; DRIVING ABILITY; EMPLOYMENT; HEALTH CARE COST; HEPATIC ENCEPHALOPATHY; HOSPITALIZATION; HUMAN; MINIMAL HEPATIC ENCEPHALOPATHY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PSYCHOMETRIC HEPATIC ENCEPHALOPATHY SCORE; PSYCHOMETRY; QUALITY OF LIFE; REVIEW; STANDARDIZATION;

DISEASE MANAGEMENT; HEPATIC ENCEPHALOPATHY; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE;

EID: 84856619987     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.12.006     Document Type: Review

References (17)

1. Schomerus H., Hamster W. Quality of life in cirrhotics with minimal hepatic encephalopathy. Metab Brain Dis 2001, 16(1-2):37-41.
2. Bajaj J.S. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008, 14(23):3609-3615.
3. Bajaj J.S., Hafeezullah M., Hoffmann R.G., et al. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol 2007, 102(9):1903-1909.
4. Kircheis G., Knoche A., Hilger N., et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 2009, 137(5):1706-1715. e1-9.
5. Groeneweg M., Quero J.C., De Bruijn I., et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology 1998, 28(1):45-49.
6. Prasad S., Dhiman R.K., Duseja A., et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 2007, 45(3):549-559.
7. Sidhu S.S., Goyal O., Mishra B.P., et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011, 106(2):307-316.
8. Bustamante J., Rimola A., Ventura P.J., et al. Prognostic significance of hepatic encephalopathy in patients with cirrhosis. JHepatol 1999, 30(5):890-895.
9. Bajaj J.S., Cordoba J., Mullen K.D., et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011, 33(7):739-747.
10. Ferenci P., Lockwood A., Mullen K., et al. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35(3):716-721.
11. Schomerus H., Hamster W. Neuropsychological aspects of portal-systemic encephalopathy. Metab Brain Dis 1998, 13(4):361-377.
12. Weissenborn K., Ennen J.C., Schomerus H., et al. Neuropsychological characterization of hepatic encephalopathy. JHepatol 2001, 34(5):768-773.
13. Iduru S., Mullen K.D. The demise of the pencil? New computer-assisted tests for minimal hepatic encephalopathy. Gastroenterology 2008, 135(5):1455-1456.
14. Prakash R., Mullen K.D. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010, 7(9):515-525.
15. Bajaj J.S., Heuman D.M., Wade J.B., et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011, 140(2):478-487.e1.
16. Mullen K.D., Amodio P., Morgan M.Y. Therapeutic studies in hepatic encephalopathy. Metab Brain Dis 2007, 22(3-4):407-423.
17. Available at: . Accessed December 24, 2011. http://www.hecme.tv.